Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma (RRMM) Patients Who Have Relapsed After Treatment With Thalidomide, Lenalidomide and Bortezomib.

NCT02461888 is registered in ClinicalTrials.gov with University of Leeds as lead sponsor.

NCT NCT02461888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02461888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma (RRMM) Patients Who Have Relapsed After Treatment With Thalidomide, Lenalidomide and Bortezomib.
Lead sponsor
University of Leeds
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2015
Completion date
January 19, 2025
Enrollment
112 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma